Travere Therapeutics (TVTX) Depreciation & Amortization (CF) (2013 - 2026)

Travere Therapeutics' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $25.2 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 96.94% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.2 million (up 57.4% YoY) and the FY2025 annual result came in at $60.7 million, up 39.46% from the prior year.
• Depreciation & Amortization (CF) was $25.2 million for Q1 2026 at Travere Therapeutics, up from $18.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $25.2 million in Q1 2026 and bottomed at -$793000.0 in Q3 2022.
• A 5-year average of $11.1 million and a median of $10.9 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) slumped 110.07% — and 2023, when it soared 1547.04%.
• Travere Therapeutics' Depreciation & Amortization (CF) stood at $6.3 million in 2022, then jumped by 50.32% to $9.5 million in 2023, then climbed by 27.43% to $12.1 million in 2024, then jumped by 50.0% to $18.1 million in 2025, then surged by 39.01% to $25.2 million in 2026.
• Business Quant data shows TVTX's Depreciation & Amortization (CF) at $25.2 million in Q1 2026, $18.1 million in Q4 2025, and $15.8 million in Q3 2025.